Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity

Molecular Cancer Therapeutics

Volumn 4, Issue 11, 2005, Pages 1729-1739

  Fellows, Ingrid M ^a   Schwaebe, Michael ^b   Dexheimer, Thomas S ^c   Vankayalapati, Hariprasad ^c   Gleason Guzman, Mary ^c   Whitten, Jeffrey P ^b   Hurley, Laurence H ^c,d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Cylene Pharmaceuticals   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYLETHER 2' ISOPROPENYL 5 METHOXYDIHYDROFURANOXANTHONE; 1 ETHOXYPSOROSPERMIN METHYL ETHER; 1 ISOPROPOXYPSOROSPERMIN METHYL ETHER; 1,3 DIHYDROXY 5 METHOXYXANTHONE; 1,5 DIMETHOXY 2' ISOPROPENYLDIHYDROFURANOXANTHONE; 1,5 DIMETHOXY 4 (1,1 DIMETHYLPROPENE)XANTHONE; 4' TERT BUTYLSILYLOXY 1,5 DIMETHOXY 3' HYDROXYDIHYDROFURANOXANTHONE; 5 O METHYLPSOROSPERMIN; ANTINEOPLASTIC AGENT; BENZYLOXY 1,5 DIMETHOXYXANTHONE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); GEMCITABINE; PLANT MEDICINAL PRODUCT; PSOROSPERMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA ALKYLATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SOLID TUMOR; STEREOCHEMISTRY; STRUCTURE ANALYSIS; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CELL LINE; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; EPOXY COMPOUNDS; INHIBITORY CONCENTRATION 50; LEUKEMIA; LYMPHOMA; MICE; MICE, NUDE; MODELS, CHEMICAL; MODELS, MOLECULAR; PANCREATIC NEOPLASMS; STEREOISOMERISM; TIME FACTORS; XANTHONES;

EID: 28044437963     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0183     Document Type: Article

References (18)

1. Kupchan SM, Streelman DR, Sneden AT. Psorospermin, a new antileukemic xanthone from Psorospermum febrifugum. J Nat Prod 1980;43:296-301.
2. Cassady JM, Baird WM, Chang CJ. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J Nat Prod 1990;53:23-41.
3. Schwaebe MK, Moran TJ, Whitten JP. Total synthesis of psorospermin. Tetrahedron Lett 2005;46:827-9.
4. Hansen M, Lee SJ, Cassady JM, Hurley LH. Molecular details of the structure of a psorospermin-DNA covalent/intercalation complex and associated DNA sequence selectivity. J Am Chem Soc 1996;118: 5553-61.
5. Kwok Y, Zang Q, Hurley LH. Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites. Proc Natl Acad Sci U S A 1998; 95:13531-6.
6. Permana PA, Ho DK, Cassady JM, Snapka RM. Mechanism of action of the antileukemic xanthone psorospermin: DNA strand breaks, abasic sites, and protein-DNA cross-links. Cancer Res 1994;54:3191-5.
7. Wang J. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
8. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994;303:681-95.
9. Osheroff N, Zechiedrich EL, Gale KC. Catalytic function of DNA topoisomerase II. BioEssays 1991;13:269-75.
10. Kwok Y, Hurley LH. Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage. J Biol Chem 1998;273:33020-6.
11. 5-methyl-(±)-(2′ R,3′ S)-psorospermin. J Org Chem 1987;52:342-7.
12. Streelman DR. The chemistry of some potent antileukemic principles from plants. Ph.D. thesis. Charlottesville (VA): University of Virginia; 1977.
13. Kim MY, Na Y, Vankayalapati H, Gleason-Guzman M, Hurley LH. Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents. J Med Chem 2003;46: 2958-72.
14. Åqvist J, Medina C, Samuuelson JE. New method for predicting binding affinities in computer-aided drug design. Protein Eng 1994;7: 385-91.
15. Åqvist J. Calculation of absolute binding free energies for charged ligands and effects of long-range electrostatic interactions. J Comput Chem 1996;17:1587-97.
16. Hayashi T, Uozumi Y, Kato K. Kyota H, Ogasawara M. Design and preparation of 3,3′-disubstituted 2,2′-bis(oxazolyl)o1,1′ binaphthyls (boxax): new chiral bis(oxazoline) ligands for catalytic asymmetric Wacker-type cyclization. J Org Chem 1999;64:1620-5.
17. Hayashi T, Uozumi Y, Kato K. Cationic palladium/boxax complexes for catalytic asymmetric Wacker-type cyclization. J Am Chem Soc 1998; 63:5071-5.
18. Hayashi T, Uozumi Y, Kato K. Catalytic asymmetric Wacker-type cyclization. J Am Chem Soc 1997;119:5063-4.